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The present investigation aimed to provide an objective narrative review of the existing literature pertaining to the
benefits and harms of marijuana use for the treatment of the most common medical and psychological conditions
for which it has been allowed at the state level. Common medical conditions for which marijuana is allowed (i.e., those
conditions shared by at least 80 percent of medical marijuana states) were identified as: Alzheimer’s disease, amyotrophic
lateral sclerosis, cachexia/wasting syndrome, cancer, Crohn’s disease, epilepsy and seizures, glaucoma, hepatitis C virus,
human immunodeficiency virus/acquired immunodeficiency syndrome, multiple sclerosis and muscle spasticity, severe
and chronic pain, and severe nausea. Post-traumatic stress disorder was also included in the review, as it is the
sole psychological disorder for which medical marijuana has been allowed. Studies for this narrative review were
included based on a literature search in PsycINFO, MEDLINE, and Google Scholar. Findings indicate that, for the
majority of these conditions, there is insufficient evidence to support the recommendation of medical marijuana
at this time. A significant amount of rigorous research is needed to definitively ascertain the potential implications
of marijuana for these conditions. It is important for such work to not only examine the effects of smoked marijuana
preparations, but also to compare its safety, tolerability, and efficacy in relation to existing pharmacological treatments.
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National estimates suggest that 5.4 million people in the
United States above the age of 12 have used marijuana
daily or regularly within the past year [1]. This represents
an increase of approximately 74.2 percent since 2006 [1].
Similar increases have also been noted among vulner-
able populations in the U.S. (e.g., veterans and adoles-
cents) [2,3].
Marijuana is currently illegal in every country in the
world. In 2012, Uruguay voted to legalize state-controlled
marijuana sales but implementation of the law has been* Correspondence: Marcel.Bonn-Miller@va.gov
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unless otherwise stated.postponed until 2015. The policy in the Netherlands is
mixed, with permissible retail sale of marijuana at coffee
shops, but restrictions on production and possession.
Notably, as the concentration of THC in marijuana has
increased, Dutch coffee shops have begun to close, as
perception of marijuana as a “soft” drug transitions to
perceptions of marijuana as a “hard” drug.
Like the Netherlands, the United States currently has a
mixed drug policy; marijuana is an illegal Schedule I
drug under U.S. Federal law. However, marijuana pol-
icies vary by state, with some states (e.g., Colorado and
Washington) legalizing the use of recreational marijuana
(i.e., allowing the legal possession and use of marijuana
under state law), and other states decriminalizing marijuana
(i.e., reducing the penalties for possession and/or use of
small amounts of marijuana to fines or civil penalties).
Furthermore, as of this review, 23 states and the District
of Columbia have passed legislation allowing medicalral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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criminal charges related to marijuana possession if a med-
ical need is documented) for the treatment of a variety of
medical and psychological conditions. Though the list of
conditions for which medical marijuana has been allowed
varies at the state level, the majority of states agree on
its use for Alzheimer’s disease (AD), amyotrophic lateral
sclerosis (ALS), cachexia/wasting syndrome, cancer,
Crohn’s disease (CD), epilepsy and seizures, glaucoma,
hepatitis C virus (HCV), human immunodeficiency virus
(HIV)/acquired immunodeficiency syndrome (AIDS),
multiple sclerosis (MS) and muscle spasticity, severe
and chronic pain, severe nausea, and post-traumatic
stress disorder (PTSD).
The aim of the present review is to provide a summary
of the existing empirical literature regarding the effects
of marijuana/cannabinoids on each of the above-noted
conditions. Though some recent work has reviewed the ad-
verse effects of marijuana [4] or the efficacy of marijuana
for certain conditions (e.g., neurologic) [5], there has yet to
be a comprehensive review of the effects of marijuana for
each of the medical and psychiatric conditions for which it
is currently used.
Methods
The list of all conditions for which medical marijuana is
allowed, according to the legislation of each U.S. state
for which medical marijuana has been approved, was
obtained and examined [6]. From this list, common
conditions for which medical marijuana is allowed (i.e.,
those conditions shared by at least 80 percent of medical
marijuana states) were identified as: AD, ALS, cachexia/
wasting syndrome, cancer, CD, epilepsy and seizures, glau-
coma, HCV, HIV/AIDS, MS and muscle spasticity, severe
and chronic pain, and severe nausea. Though not pres-
ently a qualifying condition in at least 80 percent of states
with medical marijuana laws, PTSD was also included in
the review, as it is rapidly gaining attention and recogni-
tion as the sole psychological disorder for which medical
marijuana is allowed.
Studies for this narrative review were included based on
a literature search in the following databases: PsycINFO,
MEDLINE, and Google Scholar. Within each database,
each combination of the following key marijuana terms
and the above-listed conditions were used to conduct a
search: cannabis, marijuana, marihuana, cannabinoid,
delta-9-tetrahydrocannabinol, THC, cannabidiol, CBD,
cannabinol, cannabigerol, Marinol, dronabinol, Sativex,
Nabilone, and Nabiximols. References within each ob-
tained article were also examined to assure that no studies
were overlooked. Only published, English-language studies
were included in this review.
Though the primary focus of this review is on studies
of marijuana plant effects, as these are most relevant torecent medical marijuana legislation, synthetic or plant-
derived cannabinoids (e.g., dronabinol, Nabilone) were
also included due to the general dearth of marijuana plant
studies for a number of conditions. Indeed, for pur-
poses of the review, references to oral administrations
of marijuana constitute a pharmaceutical grade extraction
administered in tablet or liquid form (e.g., dronabinol,
Nabilone, Nabiximols), while references to smoked ad-
ministration of marijuana constitute the inhalation of
smoke from burned marijuana leaves and flowers. Finally,
the present review is organized alphabetically by condition
for which marijuana is allowed, rather than in order of
disorder for which it is most to least commonly recom-
mended, or strength of the evidence. We chose this ap-
proach as there is currently only state-level data [7-9],
rather than national, representative data on the primary
conditions for which medical marijuana is used or rec-
ommended, and the existing literature and state of the
evidence for many conditions remains relatively poor.
Results
Alzheimer’s disease
AD, the leading form of dementia in the elderly, is a pro-
gressive, age-related disorder characterized by cognitive
and memory deterioration [10]. AD has several neuro-
pathological markers, including neuritic plaques and neuro-
fibrillary tangles [11]. Although several researchers have
suggested dronabinol and Nabilone may act on these
mechanisms to confer therapeutic effects for patients
with AD [12,13], a recent Cochrane systematic review
found no evidence that dronabinol was effective in re-
ducing symptoms of dementia [14]. The authors of a
placebo-controlled crossover study of 15 patients with
AD who were refusing to eat suggest that dronabinol
increases weight gain and decreases disturbed behavior
[15], but there is insufficient quantitative data to support
this conclusion [14], and one study participant had a
grand mal seizure following dronabinol administration
[15]. Another pilot study of two patients with dementia
found that dronabinol reduced nocturnal motor activity
[16]. No studies have examined the effects of smoked
marijuana in patients with AD. In sum, there is insuffi-
cient evidence to recommend marijuana for the treatment
of AD. Future directions should include conducting ran-
domized controlled trials (RCTs) comparing both smoked
and oral marijuana to placebo and existing treatments,
with sample sizes large enough to detect treatment effects
and the safety and tolerability of marijuana.
Amyotrophic lateral sclerosis
ALS is a fatal neurological disease with symptoms that
include weakness, spasticity, and respiratory difficulties.
Cannabinoids are hypothesized to act in the regions of
established pathophysiology for ALS [17] and could be
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ing, respiratory failure, dysphagia, negative mood, and dys-
autonomia) [18]. Although there is limited evidence from a
survey of patients with ALS that marijuana consumed in a
variety of forms (i.e., oral, smoked, vaporized, and eaten)
improves speech and swallowing [19], the anti-salivatory
components of marijuana may reduce the risk of aspiration
pneumonia, while also increasing patient comfort [18,19].
These survey findings indicate that up to 10 percent of
patients use marijuana for symptom management, and
these self-reports suggest efficacy in increasing appetite
and mood and decreasing pain, spasticity, and drooling.
However, as is consistent with the half-life of smoked
marijuana, the beneficial effects of marijuana on symp-
toms of ALS were fewer than 3 hours in duration [19].
The only randomized, double-blind, placebo-controlled
crossover trial of marijuana in patients with ALS has a
small sample size (N = 27) and indicates that while 5 mg
of dronabinol is well-tolerated, there was no effect on
number or intensity of cramps, quality of life, appetite,
sleep, or mood [20]. There is currently insufficient clinical
evidence in humans with ALS to recommend cannabi-
noids as primary or adjunctive therapy.
Cachexia/wasting syndrome
Cachexia is the general wasting and malnutrition that oc-
curs in the context of chronic diseases such as HIV/AIDS
and cancer. In patients with HIV or cancer, smoked
marijuana and dronabinol have been shown to increase
weight gain [21,22] and food intake [22,23] compared
to placebo. In a within-subject, double-blind, staggered,
double-dummy study of nine individuals with muscle mass
loss, dronabinol resulted in significantly greater calorie
consumption than smoked marijuana [24]. A within-
subject, double-blind, placebo-controlled trial with seven
HIV-positive marijuana smokers taking antiretroviral med-
ications found that compared to placebo, dronabinol in-
creased caloric intake [25]. Additional studies indicate that
dronabinol administration increases appetite, decreases
nausea, and protects against weight loss [26], with ef-
fects on appetite and weight stability enduring in long-
term follow-up [27].
Both dronabinol and smoked marijuana increase the
number of eating occasions [22,25], and smoked marijuana
may also affect weight gain and calorie intake by modulat-
ing appetite hormones [28]. Importantly, weight gain in
one study was greater than would have been expected
based on increased calorie consumption alone [23], which
may be particularly relevant for those who have impaired
food intake and/or nausea. These studies demonstrate
that marijuana has positive effects on cachexia resulting
from a medical condition, but are largely limited by small
sample sizes. Additionally, studies comparing THC to
FDA-approved medication (i.e., megestrol) indicate thatTHC is less effective in promoting appetite and weight
gain [29]. In sum, there is moderate support for the use
of cannabinoids for cachexia/wasting, and dronabinol
has been FDA-approved for anorexia associated with
weight loss in individuals with AIDS. Additional studies
with larger sample sizes that examine the efficacy of
marijuana compared to nutritional support/calorie aug-
mentation in the treatment of cachexia are indicated.
Cancer
Cancer is a qualifying medical condition in every state that
has approved marijuana for medical use [30]. The majority
of clinical research examining the relation between THC
and cancer has evaluated the effect of smoked THC on
the risk for cancer, or the palliative effects of THC on
chemotherapy-related nausea and emesis, chronic pain,
and wasting (reviewed in respective sections); few stud-
ies have studied the effect of marijuana in any form on
the treatment of primary cancer pathology. In vitro and
in vivo research suggests that cannabinoids inhibit tumor
growth [30] via several proposed mechanisms (e.g., sup-
pression of cell proliferation, reduced cell migration, in-
creased apoptosis) [31]; however, in vitro and in vivo
studies also have shown that THC increases tumor growth
due to reduced immune response to cancer [32]. The only
clinical trial of THC on cancer examined intracranial ad-
ministration of THC to nine patients with recurrent
glioblastoma multiforme who had failed surgical- and
radiotherapy, and results indicated that THC decreased
tumor growth, while being well-tolerated with few psy-
chotropic effects [33]. This study is limited by lack of
generalizability, and clinical trials with larger represen-
tative samples that examine oral or smoked administra-
tion of THC are essential to elucidate the effects on
cancer pathology. There is currently insufficient evidence
to recommend marijuana for the treatment of cancer, but
there may be secondary treatment effects on appetite and
pain.
Crohn’s disease
CD is an inflammatory bowel disease (IBD) that has no
cure; treatment targets include reducing inflammation
and secondary symptoms. Between 16 percent and 50
percent of patients use marijuana to relieve symptoms of
IBD [34-36], and patients using marijuana for 6 months
or longer are five times more likely to have had surgery
for their IBD [34]; whether marijuana exacerbates dis-
ease progression or more severe disease results in self-
medication is unclear. Only one placebo-controlled study
of the effects of marijuana in patients with CD has been
conducted [37]. This study found that there was no differ-
ence between placebo and smoked marijuana on CD re-
mission (defined as a CD Activity Index (CDAI) of less
than 100), and that marijuana was superior to placebo in
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greater than 100), reducing steroid use, and improving
sleep and appetite [37]. Importantly, this study did not
include objective measurement of inflammatory activity,
and there was no significant difference in placebo and
treatment groups 2 weeks after treatment cessation
[37]. Until clinical trials with objective measurement
of treatment effects over an extended period of time
are conducted to examine the safety and efficacy of
marijuana for the treatment of IBD, there is insufficient
evidence for the use of marijuana for the treatment
of IBD.
Epilepsy and seizures
The known effects of cannabinoids on epilepsy and sei-
zures are largely from animal studies, surveys, and case
studies. Several animal studies indicate that marijuana
and its constituents exhibit anticonvulsant effects [38-41]
and reduce seizure-related mortality [39], but there is also
evidence that cannabinoids can lower the threshold for
seizures [42], and THC withdrawal increases susceptibility
for convulsions [42]. Cross-sectional surveys indicate that
16–21 percent of patients with epilepsy smoke marijuana
[43,44], with some reporting positive effects (e.g., spasm
reduction) and a belief that marijuana is an effective ther-
apy [44], and others reporting increased seizure frequency
and intensity [43]. Based on a Cochrane review, the few
RCTs that have been conducted in humans include a total
of 48 participants [45] and only examine treatment with
cannabidiol. These trials exhibited heterogeneity of effects:
some indicated a reduction in seizure frequency [46,47],
while others demonstrated no effect compared to placebo
[48]. In addition, none of the studies examined response
at greater than 6-month follow-up [45]. Systematic reviews
of the literature have concluded that there is insufficient
clinical data to support or refute the use of cannabinoids
for the treatment of epilepsy and seizures [5,45].
Glaucoma
Glaucoma is a neurodegenerative eye disease that can
cause blindness by damaging retinal ganglion cells and
axons of the optic nerve. Intraocular pressure (IOP) can
influence both onset and progression of glaucoma and
is often a target for intervention. Small samples have
demonstrated reduced IOP following smoked marijuana
[49,50], but the effect is only present in 60–65 percent
of individuals [51] and lasts for 3–4 hours, requiring re-
peated dosing throughout the day [52]. Furthermore,
patients discontinue marijuana use due to side effects
(e.g., dizziness, anxiety, dry mouth, sedation, depression,
confusion, weight gain, and distortion of perception [53]),
and this treatment discontinuity may exacerbate optic
nerve damage and obviate the benefits of reduced IOP
[54]. Limited research and documented toxicity haveresulted in the American Glaucoma Society [54], Canadian
Opthalmological Society [55], and the American Academy of
Ophthalmology’s Complementary Therapies Task Force [52]
determining that there is insufficient evidence to indicate that
marijuana is safer or more effective than existing pharmaco-
therapy or surgery for the reduction of IOP. Development of
eye drops for topical application of THC would minimize
psychoactive and other side effects but is complicated by the
high lipophilicity and low water solubility of cannabinoids
[52,56]. Additionally, the distance from the application site to
the retina may be too great to afford neuroprotective benefits
[52], given that only 5 percent of an applied dose pene-
trates the cornea to the intraocular space [56].
Hepatitis C virus
There have been no RCTs examining the use of cannabi-
noids on HCV infection. Of the studies that have been
conducted, one longitudinal study demonstrates that
smoked marijuana has no effect on HCV progression in
individuals with HIV [57]. In contrast, individuals with
HCV who smoke marijuana have a higher fibrosis pro-
gression rate [58] and more severe steatosis [59], with
daily smokers having a more rapid rate of progression
and greater severity [60] than occasional marijuana users
[58,59]. Marijuana may have independent negative effects
on steatosis [59], but because none of these findings were
in the context of a clinical trial, these correlations are
not causal and it is possible that individuals who use
marijuana do so to manage greater symptom severity [60].
There may be secondary effects of cannabinoids on
HCV treatment side effects: dronabinol and Nabilone sta-
bilized treatment-induced weight-loss [61]; and dronabi-
nol, Nabilone, and marijuana procured from a marijuana
club (dose and method of administration unspecified)
increased HCV treatment duration and reduced post-
treatment virological relapse [61,62]. However, there is
also a potential drug-drug interaction between ribavirin,
a traditional HCV treatment, and marijuana due to shared
cytochrome 450 metabolism [63]. Because 90 percent of
HCV infections are the result of injection drug use [64],
treatment of symptoms with marijuana may be contra-
indicated for this subpopulation, particularly because
marijuana use in the context of other substance use (i.e.,
alcohol) has multiplicative effects on the odds of fibrosis
severity [60]. Given that newer treatments for HCV (e.g.,
sofosbuvir) are replacing ribavirin, there will likely be less
need for use of marijuana in management of treatment-
related side effects. In sum, there is currently insufficient
empirical support to recommend marijuana for the treat-
ment of HCV.
HIV/AIDS
Marijuana use in HIV-infected patients is typically for
the management of side effects (e.g., nausea) of older
Belendiuk et al. Addiction Science & Clinical Practice  (2015) 10:10 Page 5 of 10antiretroviral treatments and AIDS-related symptoms,
including weight-loss and HIV-associated neuropathy (cov-
ered in cachexia and pain sections, respectively). Survey
studies indicate that 23 percent of patients with HIV/AIDS
smoked marijuana in the past month and do so largely to
improve mood and appetite and reduce pain [65]; these pa-
tients may exhibit tolerance and need higher doses of THC
than are currently approved by the FDA for use in clinical
trials [25] to experience treatment effects. The few RCTs
that have been conducted in a small number of patients
with HIV/AIDS largely examined the effects of marijuana
(synthetic or natural marijuana that is smoked or ingested)
on symptoms (e.g., nausea and appetite) over a short
treatment window (21–84 days; see [66] for systematic
review). Studies examining the effects of marijuana on
the pharmacokinetics of antiretroviral medication dem-
onstrated that neither smoked marijuana nor dronabinol
affects short-term clinical outcomes (e.g., viral load, CD4
and CD8 counts [67]), influences the efficacy of antiretro-
viral medication [68], or indicates that dose adjustments
for protease inhibitors are necessary [21]. However, in-
dividuals who are dependent on marijuana have dem-
onstrated poorer medication adherence and greater HIV
symptoms and side effects than nonusers and nonde-
pendent users [69]. Furthermore, while some studies
have no participant withdrawal due to adverse events
[21,70,71], others reported treatment-limiting adverse
events [26,72,73]. Finally, because drug use is a risk fac-
tor for HIV infection [74], treatment of symptoms with
marijuana may be contraindicated for this subpopula-
tion. In sum, there is variability in short-term outcomes
and insufficient long-term data addressing the safety and
efficacy of marijuana when used to manage symptoms of
HIV/AIDS and its role in those also using newer, better-
tolerated antiretroviral agents.
Multiple sclerosis and muscle spasticity
Muscle spasticity, a common feature of MS, is disordered
sensorimotor control that leads to involuntary muscle ac-
tivation [75] that results in pain, sleep disturbance, and in-
creased morbidity [76]. The majority of studies examining
spasticity have compared oral or sublingual forms of
cannabinoids to placebo and found reduced spasm se-
verity [77-84], with symptom improvement enduring at
long-term follow-up [85-87], and also reduced spasm fre-
quency and spasm-related pain and sleep disturbances
[77,88,89]. With regard to smoked marijuana, one study
found reductions in muscle spasticity [90]; however, an-
other study showed that smoking marijuana impaired
posture and balance in individuals with spasticity [91],
so there is currently insufficient evidence to determine
the efficacy of smoked marijuana on spasticity [5].
Surveys of patient populations show that between 14
and 16 percent of patients with MS report using marijuanafor symptom management [92,93] and that compared to
non-marijuana-using individuals with MS, marijuana-using
individuals with MS have decreased cognitive functioning
[90,94,95]. Because cognitive dysfunction is present in
40–60 percent of individuals with MS before marijuana
administration [96], marijuana use may further comprom-
ise impaired cerebral functioning in a neurologically
vulnerable population. Additionally, future studies should
carefully consider outcome assessment. The primary methods
of measuring spasticity, the Ashworth Scale and patient
self-report, may not be appropriate measures because
antispastic drugs do not decrease Ashworth ratings, and
patient-reported spasticity severity may be poorly corre-
lated with patient functioning (i.e., a patient whose spasti-
city compensated for motor weakness may be unable to
ambulate with reduced spasticity) [97]. Importantly for
both MS and other neurological disorders, the American
Academy of Neurology does not advocate the use of
marijuana for the treatment of neurological disorders, due
to insufficient evidence regarding treatment efficacy [98].
Post-traumatic stress disorder
There has been a recent emergence of empirical studies
of the effects of marijuana on symptoms of PTSD, borne
primarily out of the observation that individuals with
PTSD report using marijuana to cope with PTSD symp-
toms; specifically, hyperarousal, negative affect, and sleep
disturbances [99-101]. Empirical work has consistently
demonstrated that the endocannabinoid system plays a
significant role in the etiology of PTSD, with greater
availability of cannabinoid type 1 receptors documented
among those with PTSD than in trauma-exposed or healthy
controls [102,103]. Though the use of marijuana and
oral THC [104,105] have been implicated as a potential
mechanism for the mitigation of many PTSD symptoms
byway of their effects on the endocannabinoid system, some
researchers caution that endocannabinoid activation with
plant-based extracts over extended periods may lead to a
number of deleterious consequences, including receptor
downregulationandaddiction [102].
There have been no RCTs of marijuana for the treat-
ment of PTSD, though there has been one small RCT of
Nabilone that showed promise for reducing nightmares
associated with PTSD [106]. One unpublished pilot study
of 29 Israeli combat veterans showed reductions in PTSD
symptoms following the administration of smoked marijuana,
with effects seen up to one year post-treatment [107].
Remaining studies have been primarily observational in
nature, documenting that PTSD is associated with greater
odds of a cannabis use disorder diagnosis [108] and
greater marijuana craving and withdrawal immediately
prior to a marijuana cessation attempt [109]. Indeed, sleep
difficulties (a hallmark of PTSD) have been associated
with poor marijuana cessation outcomes [110,111], while
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PTSD treatment outcomes [112]. Given the lack of RCTs
studying marijuana as a treatment for PTSD, there is
insufficient scientific evidence for its use at this time.
Severe and chronic pain
Clinical trials have examined smoked and oral administra-
tion of cannabinoids on different types of pain (e.g., neuro-
pathic, post-operative, experimentally induced) in multiple
patient populations (e.g., HIV, cancer, and fibromyalgia).
Two meta-analyses have been conducted examining the as-
sociation between marijuana and pain. In the first, 18 RCTs
demonstrated that any marijuana preparation containing
THC, applied by any route of administration, significantly
decreased pain scores from baseline compared to placebo
[113]. The second examined 19 RCTs of smoked marijuana
in individuals with HIV, which also indicated greater ef-
ficacy in reducing pain (i.e., sensory neuropathy) compared
to placebo [114]. Importantly, the first meta-analysis
showed that marijuana increased the odds of altered
perception, motor function, and cognition by 4 to 5
times [113], and the second study did not recommend
marijuana as routine therapy [114]. Dosage is an im-
portant factor to consider for administration of canna-
binoids for pain management, as some studies have found
that higher doses of smoked marijuana are associated with
improved analgesia [115], whereas other studies show that
higher doses of smoked marijuana increase pain response
[116]. Because the analgesic effects of marijuana are
comparable to those of traditional pain medications [117],
future research should aim to identify which analgesics
provide the lowest risk profile for the management of
severe and chronic pain. Although there is preliminary
support to suggest that marijuana may have analgesic
effects, there is insufficient research on dosing and side
effect profile, which precludes recommending marijuana
for the management of severe and chronic pain.
Severe nausea
The majority of research related to the effects of
marijuana on severe nausea has involved oral administration
of marijuana to individuals with chemotherapy-induced
nausea and vomiting (CINV). Oral marijuana (i.e., THC
suspension in sesame oil and gelatin) has been shown
to be more effective in reducing CINV than placebo [118],
including the number and volume of vomiting episodes,
and the severity and duration of nausea [119]. When com-
pared to traditional anti-emetics, some meta-analytic re-
views indicate that oral THC is more effective in reducing
CINV [120-123], others find no significant difference
[122,124-126], and another suggests that combining both
is the most effective at reducing the duration and severity
of CINV than either alone [127]. Recent advances in both
anti-emetic agents and the mechanisms of cannabinoidadministration (i.e., sublingual application) warrant future
research.
Importantly, patients receiving cannabinoids for severe
nausea reported toxicities, including paranoid delusions
(5%), hallucinations (6%), and dysphoria (13%) [122]. Add-
itionally, cannabinoid hyperemesis syndrome has been doc-
umented, in which persistent and regular marijuana use
(i.e., daily or weekly use for more than 1 year) is associ-
ated with cyclic vomiting (i.e., episodic nausea and vomiting)
[128] and nonresponse to treatment for cyclic vomiting
[129]. Dronabinol has been FDA-approved for CINV in
individuals who have not shown a treatment response
to traditional anti-emetics, but in line with recommen-
dations from the American Society of Clinical Oncology
[130] and the European Society for Medical Oncology
[131], cannabinoids should not be utilized as a first-line
treatment for nausea and vomiting.
Conclusions
The reviewed literature highlights the dearth of rigorous
research on the effects of marijuana for the most com-
mon conditions for which it is currently recommended.
It is paramount that well-designed RCTs with larger sam-
ple sizes be conducted to determine the actual medical
benefits and adverse effects of marijuana for each of the
above conditions. Indeed, recent reviews [4,132] compre-
hensively discuss adverse events associated with marijuana
use, and while it is beyond the scope of the current paper
to review these effects in-depth, they are important to
consider when evaluating whether or not to recommend
marijuana for a medical or psychiatric disorder in place of
other existing treatment options.
Given the extensive literature speaking to the harms
associated with marijuana use, research on the compara-
tive safety, tolerability, efficacy, and risk of marijuana
compared to existing pharmacological agents is needed.
The present literature also illuminates the need for re-
search into the effects of isolated cannabinoids (e.g., THC,
CBD) as well as species of smoked marijuana (e.g., indica
and sativa), as the majority of medical marijuana users in-
gest marijuana by smoking the marijuana plant [133,134],
which contains a wide variety of phytocannabinoids at
varying potencies [135,136]. Furthermore, improved and
objective measurement of clinical outcomes should be
implemented in clinical trials to determine treatment
efficacy. Finally, little research has considered the issues
of dose, duration, and potency. If research identifies a
therapeutic effect of marijuana for medical or psychiatric
conditions, there will need to be revisions in marijuana
policy to increase quality control so that dose and potency
are valid and reliable. Additionally, risk of abuse and diver-
sion can be decreased by developing prescribing practices
with continued supervision of a medical professional, cre-
ating prescription monitoring programs to reduce the risk
Belendiuk et al. Addiction Science & Clinical Practice  (2015) 10:10 Page 7 of 10of “doctor shopping”, and identifying provisions for the
safe disposal of unused cannabinoids. In sum, the current
literature does not adequately support the widespread
adoption and use of marijuana for medical and psychiatric
conditions at this time.
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